BTG 4247

Drug Profile

BTG 4247

Alternative Names: CAPAH

Latest Information Update: 28 Sep 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer BTG
  • Class Antidementias; Antidepressants; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 28 Sep 2001 No-Development-Reported for Depression in United Kingdom (Unknown route)
  • 28 Sep 2001 No-Development-Reported for Alzheimer's disease in United Kingdom (Unknown route)
  • 14 Feb 2001 A study has been added to the Alzheimer's Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top